Importantly, recent studies have demonstrated beneficial effects of XO inhibitors against the occurrence and/or progression of several disorders, particularly atherosclerosis and nonalcoholic steatohepatitis (NASH), both of which are associated with insulin resistance, hyperlipidemia, and/or obesity. This evidence concerns the gene XDH and metabolic dysfunction-associated steatohepatitis.